Tirzepatide
Tirzepatide
Tirzepatide (pronunciation: /tɪrˈzɛpətaɪd/) is a novel investigational peptide drug that is being developed for the treatment of type 2 diabetes and obesity. It is a dual GLP-1 and GIP receptor agonist that is designed to control blood glucose levels and body weight.
Etymology
The name "Tirzepatide" is derived from the combination of two words. "Tir" is a prefix used in pharmaceutical nomenclature to denote a three-point attachment, referring to the drug's dual agonist action on GLP-1 and GIP receptors. "Zepatide" is a suffix used in pharmaceutical nomenclature to denote peptide drugs.
Mechanism of Action
Tirzepatide works by mimicking the effects of the natural hormones GLP-1 and GIP. These hormones are released in response to food intake and play a crucial role in regulating blood glucose levels and body weight. By activating both GLP-1 and GIP receptors, Tirzepatide enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces food intake, thereby improving glycemic control and promoting weight loss.
Clinical Trials
Tirzepatide is currently in Phase 3 clinical trials for the treatment of type 2 diabetes and obesity. Preliminary results have shown that it significantly improves glycemic control and reduces body weight in patients with type 2 diabetes.
Related Terms
- Peptide
- Type 2 diabetes
- Obesity
- GLP-1
- GIP
- Gastric emptying
- Insulin
- Blood glucose levels
- Clinical trials
External links
- Medical encyclopedia article on Tirzepatide
- Wikipedia's article - Tirzepatide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski